AGGAME

Hepatology£ºHBV pgRNA¿ÉÓÃÓÚÒÒ¸ÎÏà¹Ø¸Î°©µÄÖ×Áö·ÖÐͺÍÔ¤ºóÕ¹Íû

Ðû²¼£º2017-08-23¡¡|¡¡ÈªÔ´£º¹ú¼Ê¸Î²¡Íø¡¡|¡¡ä¯ÀÀ£º11554

·¨¹ú¹ú¼Ò¿µ½¡ºÍҽѧÑо¿ÔºHalgandµÈ¿ËÈÕÍê³ÉµÄÒ»ÏîÑо¿Åú×¢£¬¸Îϸ°û°©£¨HCC£©»¼ÕßµÄÖ×Áö×éÖ¯Öпɼì³öHBV¸´ÖÆ£¬´ú±í¾ßÓÐת¼×éÑ§ÌØÕ÷µÄÖ×ÁöÇÖÕ¼ÐÔ½ÏÈõµÄÒ»¸öÑÇÐÍ£¬Ç°»ùÒò×éRNA£¨pgRNA£©¿É×÷Ϊ²¡¶¾¸´Öƺͻ¼ÕßÔ¤ºóµÄѸËÙ±ê¼ÇÎï¡£

¸ÃÏîÑо¿ÄÉÈë99ÀýHBsAgÑôÐÔ¡¢²¡¶¾Ñ§»ñµÃÒÖÖÆ¡¢½ÓÊÜÖ×ÁöÇгý»ò¸ÎÒÆÖ²µÄHCC»¼Õߣ¬ÆÊÎöÖ×ÁöºÍ·ÇÖ×Áö¸ÎÔàÑù±¾ÖеIJ¡¶¾ºÍϸ°û²ÎÊý£¬¶Ô×ÜHBV DNAºÍRNA¡¢¹²¼Û±ÕºÏ»·×´DNA£¨cccDNA£©ÒÔ¼°pgRNAµÈHBVÔ˶¯ÐÔ¸´ÖƵıê¼ÇÎï¾ÙÐмì²â¡£

Ч¹ûÏÔʾ£¬ÔÚ´ó´ó¶¼²¡ÀýµÄÖ×ÁöºÍ·ÇÖ×Áö¸Î×éÖ¯ÖУ¬¾ù¿É¼ì³ö×ÜHBV DNAºÍRNA¡£ÔÚ´ó´ó¶¼·ÇÖ×Áö¸Î×éÖ¯Öпɼì³öHBV cccDNAºÍpgRNA£¨¼ì³öÂÊ»®·ÖΪ66%ºÍ90%£©£¬Ïà±È֮ϣ¬Ö»Óв¿·ÖÖ×ÁöÑù±¾Öпɼì³öHBV cccDNAºÍpgRNA£¨¼ì³öÂÊ»®·ÖΪ39%ºÍ67%£¬P<0.01£©¡£

¶Ô11ÀýÔ´ÓÚÓÎÀë»ùÒòÐÎʽµÄX»ùÒò¾ÙÐвâÐòÅú×¢£¬Ö×ÁöºÍÆ¥ÅäµÄ·ÇÖ×Áö¸Î×éÖ¯ÖеÄHBV»ùÒòÐͲ¢²»Ïàͬ£¬ÕâΪÖ×Áö×éÖ¯ÖеÄHBV¸´ÖÆÌṩÁ˽øÒ»²½Ö¤¾Ý¡£ÆÊÎöÅú×¢£¬Ö×Áö×éÖ¯Öпɼì³öpgRNAºÍcccDNA£¬Óë䱬·¢Ö×Áö΢Ѫ¹ÜÇÖÕ¼ºÍ»¼ÕßÉúÑÄÂʽϸßÓйØ¡£Í¨¹ýAgilent΢ÕóÁжԻùÒò±í´ï¾ÙÐÐÆÊÎöÅú×¢£¬pgRNAÑôÐÔHCC£¬Æäϸ°ûÖÜÆÚºÍDNAÐÞ¸´±ê¼ÇÎïµÄˮƽ½ÏµÍ£¬²¢ÇÒ±í´ïHBVÊÜÌå-ÄÆÀë×Ó-Å£»Çµ¨ËṲתÔ˶àëÄ£¨NTCP£©£¬Åú×¢Ö×ÁöµÄ·Ö½âÓÅÒì¡£

ÐÅÔ´£ºWang Y, Xiong J, Niu M, et al. Statins and the Risk of Cirrhosis in Hepatitis B or C Patients: A Systematic Review and Dose-response Meta-analysis of Observational Studies. Oncotarget. 2017 Jul 27.

Ïà¹ØÐÂÎÅ

ÁªÏµ·½·¨
µç»°£º0591-38265199
´«Õ棺0591-83228265
ҽѧ×ÉѯÈÈÏߣº400-8875-001
²»Á¼·´Ó¦±¨¸æ£ºÓÊÏ䣺pvd@cosunter.com£»pv@akeylink.cn ÔÚÏßÌ£ºÁ´½Ó
Ò½Ò©´ú±í±¸°¸£ºÁ´½Ó
¹«Ë¾µØµã£º¸£½¨Ê¡¸£ÖݸßÐÂÇøÎÚÁú½­ÖдóµÀ7ºÅÁ¢ÒìÔ°¶þÆÚ16ºÅÂ¥
Éú²ú»ùµØ£º¸£½¨Ê¡èÏÈÙÏØ¶«Ô´Ï縻Դ¹¤ÒµÇø
ɨÂë¹Ø×¢

AGGAME΢ÐŹ«ÖÚºÅ

AGGAME¸ÊÓÑÖ®¼Ò΢ÐŹ«ÖÚºÅ
×ʸñÖ¤Êé±àºÅ£º(Ãö)-·Çı»®ÐÔ-2014-0006 2015 AGGAME ÃöICP±¸11026770ºÅ

Ãö¹«Íø°²±¸ 35092602000113ºÅ

ÍøÕ¾µØÍ¼